Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
Order: Signal: Tickers:
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 2 #1 Type: candle | line | technical    Timeframe: daily | intraday    Auto Refresh: 3min | off
TickerKALV [NASD]
CompanyKalVista Pharmaceuticals, Inc.
CountryUSA
IndustryBiotechnology
Market Cap247.84MEPS (ttm)-1.64
P/E-EPS this Y-18.80%
Forward P/E-EPS next Y-6.50%
PEG-EPS past 5Y33.10%
P/S19.51EPS next 5Y-
P/B2.90EPS Q/Q25.60%
Dividend-Sales Q/Q31.00%
Insider Own9.57%Inst Own89.70%
Insider Trans0.00%Inst Trans1.70%
Short Float1.97%EarningsSep 14/b
Analyst Recom1.50Target Price-
Avg Volume122.28K52W Range5.61 - 18.96
Sep-14-20 07:00AMKalVista Pharmaceuticals Reports First Fiscal Quarter Results Business Wire
Sep-11-20 07:00AMKalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference Business Wire
Aug-27-20 11:06AMIntroducing KalVista Pharmaceuticals (NASDAQ:KALV), A Stock That Climbed 93% In The Last Three Years Simply Wall St.
Aug-07-20 09:24AMWere Hedge Funds Right About Piling Into KalVista Pharmaceuticals, Inc. (KALV)? Insider Monkey
Aug-03-20 07:30AMKalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference Business Wire
Jul-02-20 07:55AMNeed To Know: Analysts Are Much More Bullish On KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Revenues Simply Wall St.
Jul-01-20 07:00AMKalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results Business Wire
Jun-23-20 07:04PMHedge Funds Are Buying KalVista Pharmaceuticals, Inc. (KALV) Insider Monkey
Jun-15-20 09:57AMBenzinga's Top Upgrades, Downgrades For June 15, 2020 Benzinga
May-28-20 07:30AMKalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference Business Wire
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yea ChristopherChief Development OfficerFeb 05Sale17.101001,71082,869Feb 07 05:18 PM
Feener Edward P.Chief Scientific OfficerFeb 05Sale17.111001,71196,634Feb 07 05:17 PM
Crockett Thomas AndrewCEOFeb 05Sale17.052003,410238,220Feb 07 05:14 PM
Yea ChristopherChief Development OfficerDec 20Option Exercise0.002,6461185,615Dec 26 05:32 PM
Crockett Thomas AndrewCEODec 20Sale17.022,30039,150238,420Dec 26 05:30 PM
TickerRUHN [NASD]
CompanyRuhnn Holding Limited
CountryChina
IndustryInternet Retail
Market Cap229.80MEPS (ttm)-0.16
P/E-EPS this Y-25.70%
Forward P/E28.80EPS next Y-
PEG-EPS past 5Y-
P/S1.21EPS next 5Y-
P/B1.40EPS Q/Q7.70%
Dividend-Sales Q/Q-3.80%
Insider Own12.80%Inst Own4.40%
Insider Trans0.00%Inst Trans-6.07%
Short Float0.14%EarningsSep 14/b
Analyst Recom2.00Target Price-
Avg Volume138.80K52W Range2.49 - 9.60
Sep-14-20 03:30AMRuhnn Announces First Quarter of Fiscal Year 2021 Unaudited Financial Results GlobeNewswire
Aug-31-20 06:00AMRuhnn to Report First Quarter of Fiscal Year 2021 Financial Results on Monday, September 14, 2020 GlobeNewswire
Aug-14-20 04:27PMRuhnn Announces Filing of Fiscal Year 2020 Annual Report on Form 20-F and Changes to its Board of Directors GlobeNewswire
Jul-13-20 06:37AMRuhnn Announces RMB100 Million Initiative to Identify and Invest in Top KOLs GlobeNewswire
Jun-17-20 06:00AMRuhnn to Participate in Upcoming June Investor Conferences GlobeNewswire
Jun-03-20 05:30PMRuhnn Holding Ltd (RUHN) Q4 2020 Earnings Call Transcript Motley Fool
Jun-03-20 04:00AMRuhnn Announces Fourth Quarter and Full Fiscal Year 2020 Unaudited Financial Results GlobeNewswire
Jun-02-20 06:00AMRuhnn Announces up to US$15 Million Share Repurchase Program GlobeNewswire
May-27-20 06:00AMRuhnn to Participate in Upcoming Investor Conferences GlobeNewswire
May-21-20 04:00PMRuhnn to Report Fourth Quarter and Full Fiscal Year 2020 Financial Results on June 3, 2020 GlobeNewswire
Ruhnn Holding Limited, together with its subsidiaries, operates key opinion leader (KOL) cultivation and incubation platforms in the People's Republic of China. The company engages in the sale of various fashion and lifestyle products to consumers through its KOL online stores; and provision of various KOL sales and advertising services to third-party merchants. Its online stores primarily provide women's apparel, cosmetics, shoes, and handbags. As of March 31, 2020, it owned and operated 19 online stores; and had 168 signed KOLs. The company was founded in 2016 and is headquartered in Hangzhou, the People's Republic of China.
1